Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyLin Shen, Ningning Ding, Roberto Pazo-Cid et al.|Journal of Clinical Oncology|2022Cited by 306